KRAS and cancer: Furthermore, we observed upregulation of the TNFα-NFκB and Kras signaling pathways in the C1 subtype, which have been implicated in the progression and drug resistance of various cancers (Girouard et al. 2020; Timar and Kashofer 2020; Kim et al. 2023).